Ken and Jane Gremling have shared everything since they got married in 1971, just three weeks after they started dating.
But they never expected to receive identical breast cancer diagnoses within 6 months of each other.
The grandparents-of-one, and co-owners of a real estate firm in Amherst, Ohio, were both diagnosed with estrogen-positive tumors in their right breasts last winter, and both needed mastectomies to remove them.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.